Cargando…
One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre
BACKGROUND: Following optimal local therapy, adjuvant Procarbazine, Lomustine and Vincristine (PCV) improves overall survival (OS) in low-grade glioma (LGG). However, 1 year of PCV is associated with significant toxicities. In the pivotal RTOG 9802 randomised control trial, approximately half of the...
Autores principales: | Keogh, Rachel J., Aslam, Razia, Hennessy, Maeve A., Coyne, Zac, Hennessy, Bryan T., Breathnach, Oscar S., Grogan, Liam, Morris, Patrick G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869199/ https://www.ncbi.nlm.nih.gov/pubmed/33557783 http://dx.doi.org/10.1186/s12885-021-07809-5 |
Ejemplares similares
-
Toxicity Profile of Procarbazine Lomustine and Vincristine Chemotherapy in Low-Grade Glioma - Retrospective Review
por: Irfan, Nabia, et al.
Publicado: (2020) -
Clinical feasibility of modified procarbazine and lomustine chemotherapy without vincristine as a salvage treatment for recurrent adult glioma
por: Ahn, Stephen, et al.
Publicado: (2022) -
Efficacy of Procarbazine, Lomustine, and Vincristine Chemotherapy for Recurrent Primary Central Nervous System Lymphomas
por: Kim, Young-Joo, et al.
Publicado: (2015) -
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors
por: Lassman, Andrew B., et al.
Publicado: (2022) -
A comparative study of the effectiveness and safety of combined procarbazine, lomustine, and vincristine as a therapeutic method for recurrent high-grade glioma: A protocol for systematic review and meta-analysis
por: Cai, Yang, et al.
Publicado: (2020)